-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptevo Therapeutics Announces 100% Remission Rate in Cohort 3 of RAINIER Trial for AML with Mipletamig, Opens Enrollment for Cohort 4

Reuters·09/16/2025 12:30:51

Please log in to view news